Dexpramipexole Attenuates White Matter Injury to Facilitate Locomotion and Motor Coordination Recovery via Reducing Ferroptosis after Intracerebral Hemorrhage
Open Access
- 4 August 2022
- journal article
- research article
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2022 (1) , 6160701
Abstract
Deciphering the factors causing damage to white matter fiber bundles and exploring new strategies to alleviate white matter injury (WMI) is a promising treatment to improve neurological impairments after intracerebral hemorrhage (ICH). Ferroptosis usually occurs at perihematomal region and contributes to neuronal death due to reactive oxygen species (ROS) production. Dexpramipexole (DPX) easily crosses the blood brain barrier (BBB) and exerts antioxidative properties by reducing ROS production, while the role of DPX in ferroptosis after ICH remains elusive. Here, our results indicated that ferroptosis played a significant role in WMI resulting from iron and ROS accumulation around hematoma. Further evidence demonstrated that the administration of DPX decreased iron and ROS deposition to inhibit ferroptosis at perihematomal site. With the inhibition of ferroptosis, WMI was alleviated at perihematomal site, thereafter promoting locomotion and motor coordination recovery in mice after ICH. Subsequently, the results showcased that the expression of glutathione peroxidase 4 (GPX4) and ferroptosis suppressing protein 1 (FSP1) was upregulated with the administration of DPX. Collectively, the present study uncovers the underlying mechanism and elucidates the therapeutic effect of DPX on ICH, and even in other central nervous system (CNS) diseases with the presence of ferroptosis.Keywords
Funding Information
- National Natural Science Foundation of China (82001321, 82001263)
This publication has 55 references indexed in Scilit:
- Dysfunction in Motor Coordination in Neonatal White Matter Injury Model without Apparent Neuron LossCell Transplantation, 2016
- Iron and Intracerebral Hemorrhage: From Mechanism to TranslationTranslational Stroke Research, 2013
- Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trialThe Lancet Neurology, 2013
- Modeling Intracerebral Hemorrhage in Mice: Injection of Autologous Blood or Bacterial CollagenaseJournal of Visualized Experiments, 2012
- Oligodendrocyte-protection and remyelination post-spinal cord injuries: A reviewProgress in Neurobiology, 2012
- Effects of dexpramipexole on brain mitochondrial conductances and cellular bioenergetic efficiencyBrain Research, 2012
- KNS‐760704 [(6R)‐4,5,6,7‐tetrahydro‐N6‐propyl‐2, 6‐benzothiazole‐diamine dihydrochloride monohydrate] for the Treatment of Amyotrophic Lateral SclerosisCNS Neuroscience & Therapeutics, 2008
- Blood–brain barrier transport of pramipexole, a dopamine D2 agonistLife Sciences, 2007
- Mechanisms of brain injury after intracerebral haemorrhageThe Lancet Neurology, 2006
- Targeted Antioxidative and Neuroprotective Properties of the Dopamine Agonist Pramipexole and Its Nondopaminergic Enantiomer SND919CL2x [(+)2-Amino-4,5,6,7-tetrahydro-6-lpropylamino-benzathiazole Dihydrochloride]The Journal of Pharmacology and Experimental Therapeutics, 2006